Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication
Journal of Clinical Laboratory Analysis · 2026-07 · 40 (13)
DOI: 10.1002/jcla.70255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Laboratory Analysis, online erschienen am 25.05.2026. Verfasst von Yanfang Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Midkine, Biomarkers, Tumor. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangxi Health Commission.
Abstract (Originalsprache)
Background
Up‐to‐date tumor markers are considered more helpful in the evaluation of treatment response and prognostication than in diagnosis. Identification of a valid biomarker to help clinical management of hepatocellular carcinoma (HCC) is still a challenge, especially in alpha‐fetoprotein (AFP) negative HCC. This study evaluated the efficacy of serum Midkine in HCC treatment response and prognostication as well as its association with clinical pathological features.
Methods
The enzyme‐linked immunosorbent assay (ELISA) was used to analyze the serum (soluble) Midkine levels in patients with benign and malignant liver disease and healthy subjects.
Results
Serum Midkine levels in HCC, hepatic cholangiocarcinoma (HC), chronic hepatitis B (CHB), and decompensated hepatic cirrhosis (DHC) patients were significantly higher than in healthy subjects and patients with benign hepatic tumors, with HCC being the highest. Serum Midkine levels were associated with patients' clinical pathologic features such as tumor size, ascites, high Child‐Pugh and BCLC stages, and advanced clinical stages. Serum Midkine was helpful in characterizing the AFP negative HCC patients. A model has been created using univariate and multivariate regression analysis of biomarkers in predicting HCC, which showed that Midkine was one of the key predictive factors in AFP negative HCC. Midkine levels as a parameter for treatment response evaluation and disease progression/prognostication are comparable to computed tomography scan (CT) and magnetic resonance imaging (MRI), especially in non‐surgical treatment patients.
Conclusion
Serum Midkine levels could be used as a parameter for evaluation of treatment efficacy and prognostication of HCC, especially in AFP‐negative HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China.
- Department of Laboratory Medicine, The Third People's Hospital of Nanning, Nanning, Guangxi, China.
ORCID-Profile: Liejun Jiang
Förderung
- Guangxi Health Commission
Zitieren
APA
Luo, Y., Lu, Q., Huang, J., & Jiang, L. (2026). Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication. Journal of Clinical Laboratory Analysis, 40(13). https://doi.org/10.1002/jcla.70255
Vancouver
Luo Y, Lu Q, Huang J, Jiang L. Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication. Journal of Clinical Laboratory Analysis. 2026;40(13). doi:10.1002/jcla.70255
BibTeX
@article{Luo2026,
author = {Luo, Yanfang and Lu, Qiuwei and Huang, Jing and Jiang, Liejun},
title = {Serum Midkine as a Biomarker for Hepatocellular Carcinoma Treatment Response and Prognostication},
journal = {Journal of Clinical Laboratory Analysis},
year = {2026},
volume = {40},
number = {13},
doi = {10.1002/jcla.70255}
}
EUVIMED